Kerry Kourepenos Portfolio
Invests via Cutter Capital Management, LP | Managed by Vincent Aita, Kerry Kourepenos
Invests via Cutter Capital Management, LP
Managed by Vincent Aita, Kerry Kourepenos
Automatically Tracked
Kerry Kourepenos Profile
Seasoned technology operator and early-stage investor, Kerry Kourepenos brings founder-level experience across product-led SaaS and developer tools. Often advising boards and angel rounds, he focuses on go-to-market scaling, monetization strategy and engineering-driven product development. Market relevance is as an operator-investor connecting technical teams with venture capital and strategic acquirers.
Seasoned technology operator and early-stage investor, Kerry Kourepenos brings founder-level experience across product-led SaaS and developer tools. Often advising boards and angel rounds, he focuses on go-to-market scaling, monetization strategy and engineering-driven product development. Market relevance is as an operator-investor connecting technical teams with venture capital and strategic acquirers.
Investment Philosophy & Strategy
Operator-driven angel and seed investor focused on product-led SaaS and developer tools, prioritizing founding teams with deep technical and go-to-market chops. Capital allocation favors early-stage equity, follow-on optional, and lean runway-extension rounds that accelerate monetization and usage-driven growth. Due diligence emphasizes engineering quality, repeatable acquisition channels, unit economics, and clear acquirer or scale paths. Decision-making is founder-centric, hands-on, and metrics-led.
Operator-driven angel and seed investor focused on product-led SaaS and developer tools, prioritizing founding teams with deep technical and go-to-market chops. Capital allocation favors early-stage equity, follow-on optional, and lean runway-extension rounds that accelerate monetization and usage-driven growth. Due diligence emphasizes engineering quality, repeatable acquisition channels, unit economics, and clear acquirer or scale paths. Decision-making is founder-centric, hands-on, and metrics-led.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
7.92%
Gain -0.94%
Monthly
0.43%
Yearly
5.26%
Drawdown
19.15%
$0
Equity
Holdings
$0
Investment
$0
$19.97M
Profit -$2.14M
Realized
$19.97M
Unrealized
$0
Dividends
$4.42M
Goals
Avg. 49.5% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-0.94%
Profit
-$2.14M
Win %
46%
This Week
Compared To Last Week
Gain
-0.13%
Profit
-$304,080.96
Win %
46%
This Month
Compared to last month
Gain
5.47%
Profit
$11.89M
Win %
46%
This Year
Compared to last year
Gain
-0.17%
Profit
-$385,475.67
Win %
51%
INSM Insmed Inc.
+$9.51M
KVUE Kenvue Inc.
+$4.95M
GILD Gilead Sciences Inc.
+$3.94M
BBIO BridgeBio Pharma, Inc.
+$3.84M
ACLX Arcellx, Inc.
+$3.76M
BCRX BioCryst Pharmaceuticals Inc.
+$3.74M
RPRX Royalty Pharma plc
+$3.67M
ABBV AbbVie Inc.
+$3.41M
JNJ Johnson & Johnson
+$3.18M
HRMY Harmony Biosciences Holdings, Inc.
+$2.91M
AMGN Amgen Inc.
+$2.84M
IOVA Iovance Biotherapeutics, Inc.
+$2.79M
EOLS Evolus Inc.
+$2.49M
TEVA Teva Pharmaceutical Industries Ltd. ADR
+$2.43M
AVTR Avantor Inc.
+$1.87M
MRK Merck & Co., Inc.
+$1.56M
VERA Vera Therapeutics Inc.
+$1.51M
JAZZ Jazz Pharmaceuticals plc
+$1.38M
PBH Prestige Consumer Healthcare Inc.
+$963,900
ROIV Roivant Sciences Ltd
+$844,000
SMMT Summit Therapeutics Inc.
+$796,000
AGIO Agios Pharmaceuticals Inc.
+$772,484.42
LEGN Legend Biotech Corporation American Depositary Shares
+$581,503
ELVN Enliven Therapeutics, Inc.
+$483,878.07
RCUS Arcus Biosciences Inc.
+$169,840.46
PFE Pfizer Inc.
+$91,276
IONS Ionis Pharmaceuticals, Inc.
+$29,906.3
APLS Apellis Pharmaceuticals Inc.
$0
AKRO Akero Therapeutics, Inc.
$0
VRNA Verona Pharma plc
$0
FOLD Amicus Therapeutics, Inc.
$0
SWTX SpringWorks Therapeutics Inc.
$0
ACAD Acadia Pharmaceuticals Inc.
-$4.24M
NTLA Intellia Therapeutics Inc.
-$3.47M
REGN Regeneron Pharmaceuticals, Inc.
-$3.43M
JANX Janux Therapeutics Inc.
-$3.18M
VRDN Viridian Therapeutics Inc.
-$3.17M
KYTX Kyverna Therapeutics, Inc.
-$2.89M
RNAM Avidity Biosciences, Inc.
-$2.71M
MRNA Moderna, Inc.
-$2.61M
AVDL Avadel Pharmaceuticals plc
-$2.23M
BMRN Biomarin Pharmaceutical Inc.
-$2.06M
NAMS NewAmsterdam Pharma Co. N.V.
-$1.76M
A Agilent Technologies Inc.
-$1.68M
CYTK Cytokinetics, Incorporated
-$1.58M
NMRA Neumora Therapeutics, Inc.
-$1.44M
LLY Eli Lilly and Company
-$1.34M
CABA Cabaletta Bio Inc.
-$1.3M
CRSP Crispr Therapeutics AG
-$1.1M
PRGO Perrigo Company plc
-$1.08M
RARE Ultragenyx Pharmaceutical Inc.
-$975,719.46
PLRX Pliant Therapeutics Inc.
-$805,593.75
MDGL Madrigal Pharmaceuticals, Inc.
-$686,160
AXSM Axsome Therapeutics, Inc.
-$556,334.13
SRPT Sarepta Therapeutics Inc.
-$542,156.5
HALO Halozyme Therapeutics Inc.
-$520,333.68
TARS Tarsus Pharmaceuticals Inc.
-$450,000
BIIB Biogen Inc.
-$434,995.22
CNTA Centessa Pharmaceuticals plc American Depositary Receipt
-$348,570.21
BMY Bristol-Myers Squibb Company
-$281,270.89
EXEL Exelixis Inc.
-$120,199.67
Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 143 | Longs Won 59/143 41% | Profit Factor 1.18 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $1.74M |
| Average Win $1.46M | Best Trade (Jun 29) $8.43M | Sharpe Ratio -10.31 |
| Average Loss -$867,031.79 | Worst Trade (Mar 30) -$4.91M | Z-Score -0.83 (59.56%) |
| Commissions $0 | Avg. Trade Length 5m 2w | Expectancy $139,654.18 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Kerry Kourepenos?
The largest contributions to the portfolio's profits come from the following stocks: Insmed Inc - $9.51M, Kenvue Inc - $4.95M, Gilead Sciences Inc - $3.94M, BridgeBio Pharma, Inc - $3.84M, and Arcellx, Inc - $3.76M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Acadia Pharmaceuticals Inc - $4.24M, Intellia Therapeutics Inc - $3.47M, Regeneron Pharmaceuticals, Inc - $3.43M, Janux Therapeutics Inc - $3.18M, and Viridian Therapeutics Inc - $3.17M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Kerry Kourepenos's portfolio generate?
The portfolio generates substantial dividend income, with a total of $4.42M earned over time. The largest contributors to dividend income include Bristol-Myers Squibb Company - $879,474.2, Gilead Sciences Inc - $706,413.4, Royalty Pharma plc - $695,912.45, Perrigo Company plc - $566,723.93, and Amgen Inc - $483,213.7. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Kerry Kourepenos's monthly returns?
Kerry Kourepenos's monthly returns show a mixed pattern. Some months are relatively calm, while others are noticeably stronger or weaker, which suggests that performance is not fully consistent over time. This points to a strategy that may offer attractive upside but can also experience uneven short-term results.
Can Kerry Kourepenos's strategy be considered aggressive or moderate?
It is difficult to clearly classify Kerry Kourepenos's strategy as aggressive or moderate based on the available data. A more complete performance and portfolio structure history would be needed to assess the overall risk profile with confidence.
Should beginners follow Kerry Kourepenos's strategy?
It is difficult to determine whether Kerry Kourepenos's strategy is suitable for beginners based on the available data. A more complete view of performance, risk, and portfolio structure would be needed for a confident assessment.
